Your browser doesn't support javascript.
loading
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.
Arena, Sabrina; Siravegna, Giulia; Mussolin, Benedetta; Kearns, Jeffrey D; Wolf, Beni B; Misale, Sandra; Lazzari, Luca; Bertotti, Andrea; Trusolino, Livio; Adjei, Alex A; Montagut, Clara; Di Nicolantonio, Federica; Nering, Rachel; Bardelli, Alberto.
Afiliação
  • Arena S; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. FIRC Institute of Molecular Oncology (IFOM), Milano 20139, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy. sabrina.arena@ircc.it alberto.bardelli@unito.i
  • Siravegna G; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy.
  • Mussolin B; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy.
  • Kearns JD; Merrimack Pharmaceuticals Inc., Cambridge, MA 02139, USA.
  • Wolf BB; Merrimack Pharmaceuticals Inc., Cambridge, MA 02139, USA.
  • Misale S; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy.
  • Lazzari L; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy.
  • Bertotti A; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy.
  • Trusolino L; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy.
  • Adjei AA; Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
  • Montagut C; Medical Oncology Department, Hospital del Mar, Barcelona 08003, Spain. Cancer Research Program, FIMIM (Hospital del Mar Medical Research Institute), Hospital del Mar, Barcelona 08003, Spain.
  • Di Nicolantonio F; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy.
  • Nering R; Merrimack Pharmaceuticals Inc., Cambridge, MA 02139, USA.
  • Bardelli A; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia (FPO), IRCCS, Candiolo, Torino 10060, Italy. Department of Oncology, University of Torino, Candiolo, Torino 10060, Italy. sabrina.arena@ircc.it alberto.bardelli@unito.it.
Sci Transl Med ; 8(324): 324ra14, 2016 Feb 03.
Article em En | MEDLINE | ID: mdl-26843189
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Resistencia a Medicamentos Antineoplásicos / Receptores ErbB / Cetuximab / Anticorpos Monoclonais / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Resistencia a Medicamentos Antineoplásicos / Receptores ErbB / Cetuximab / Anticorpos Monoclonais / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article